MC

Moelis Appoints Dr. Louise Mirrer to Board

Moelis (NYSE: MC) has appointed Dr. Louise Mirrer as an independent member to its Board of Directors, effective September 17, 2024. Dr. Mirrer brings over four decades of experience in academia and the non-profit sector, including more than 20 years of executive leadership. She has been leading the New York Historical Society as its President and CEO since 2004, significantly enhancing the institution's position as a leading cultural and educational institution. Under her leadership, the institution's annual visitorship has increased to nearly half a million, and she oversaw a $100 million capital campaign and the launch of numerous groundbreaking exhibitions.

Dr. Mirrer will join Moelis’s Board as the fourth Independent Director alongside John Allison, Kenneth Shropshire, and Laila Worrell. Additionally, Dr. Mirrer holds a double Ph.D. from Stanford, a graduate Diploma from Cambridge, and a BA magna cum laude from the University of Pennsylvania. She is also an Honorary Fellow of Wolfson College, Cambridge, and a member of the Council on Foreign Relations.

Moelis & Company is a leading global independent investment bank that provides strategic advice and solutions to a diverse client base. The firm assists its clients in achieving their strategic goals by offering comprehensive integrated financial advisory services across all major industry sectors. Moelis & Company’s experienced professionals advise clients on their most critical decisions, including mergers and acquisitions, recapitalizations and restructurings, capital markets transactions, and other corporate finance matters. The firm serves its clients from 23 locations in North and South America, Europe, the Middle East, Asia, and Australia. The market has reacted to these announcements by moving the company's shares 1.8% to a price of $69.56. For more information, read the company's full 8-K submission here.

The above analysis is intended for educational purposes only and was performed on the basis of publicly available data. It is not to be construed as a recommendation to buy or sell any security. Any buy, sell, or other recommendations mentioned in the article are direct quotations of consensus recommendations from the analysts covering the stock, and do not represent the opinions of Market Inference or its writers. Past performance, accounting data, and inferences about market position and corporate valuation are not reliable indicators of future price movements. Market Inference does not provide financial advice. Investors should conduct their own review and analysis of any company of interest before making an investment decision.

IN FOCUS